{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:05:22Z","timestamp":1792011922907,"version":"4.4.0"},"reference-count":143,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23014","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T22:15:19Z","timestamp":1690496119000},"page":"152-163","source":"Crossref","is-referenced-by-count":17,"title":["The pathobiology of follicular lymphoma"],"prefix":"10.3960","volume":"63","author":[{"given":"Joaquim","family":"Carreras","sequence":"first","affiliation":[{"name":"Department of Pathology, Tokai University, School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 de Leval L, Jaffe ES. Lymphoma Classification. Cancer J. 2020; 26: 176-185.","DOI":"10.1097\/PPO.0000000000000451"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Swerdlow SH, Campo E, Pileri SA et al.<\/i> The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Carbone A, Roulland S, Gloghini A et al.<\/i> Follicular lymphoma. Nat Rev Dis Primers. 2019; 5: 83.","DOI":"10.1038\/s41572-019-0132-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yoshino T, Takata K, Tanaka T et al.<\/i> Recent progress in follicular lymphoma in Japan and characteristics of the duodenal type. Pathol Int. 2018; 68: 665-676.","DOI":"10.1111\/pin.12733"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Campo E, Jaffe ES, Cook JR et al.<\/i> The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11): 1229-1253. Blood. 2023; 141: 437.","DOI":"10.1182\/blood.2022019016"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Campo E, Jaffe ES, Cook JR et al.<\/i> The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140: 1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Cazzola M, Sehn LH. Developing a classification of hematologic neoplasms in the era of precision medicine. Blood. 2022; 140: 1193-1199.","DOI":"10.1182\/blood.2022015849"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 de Leval L, Alizadeh AA, Bergsagel PL et al.<\/i> Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022; 140: 2193-2227.","DOI":"10.1182\/blood.2022015854"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-48.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015; 15: 137-148.","DOI":"10.1038\/nri3804"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gaber T, Buttgereit F. A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptors. Cell Mol Immunol. 2022; 19: 145-146.","DOI":"10.1038\/s41423-021-00823-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Mesin L, Ersching J, Victora GD. Germinal Center B Cell Dynamics. Immunity. 2016; 45: 471-482.","DOI":"10.1016\/j.immuni.2016.09.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Stebegg M, Kumar SD, Silva-Cayetano A et al.<\/i> Regulation of the Germinal Center Response. Front Immunol. 2018; 9: 2469.","DOI":"10.3389\/fimmu.2018.02469"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Young C, Brink R. The unique biology of germinal center B cells. Immunity. 2021; 54: 1652-1664.","DOI":"10.1016\/j.immuni.2021.07.015"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 K\u00fcppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med. 1999; 341: 1520-1529.","DOI":"10.1056\/NEJM199911113412007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Wartenberg M, Vasil P, zum Bueschenfelde CM et al.<\/i> Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse. Haematologica. 2013; 98: 1433-1441.","DOI":"10.3324\/haematol.2012.074252"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Klien U, Goossens T, Fischer M et al.<\/i> Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1998; 162: 261-280.","DOI":"10.1111\/j.1600-065X.1998.tb01447.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Halld\u00f3rsd\u00f3ttir AM, Fr\u00fchwirth M, Deutsch A et al.<\/i> Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma. Leuk Res. 2008; 32: 1015-1021.","DOI":"10.1016\/j.leukres.2007.11.028"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kosmas C, Stamatopoulos K, Papndoki T et al.<\/i> Somatic hypermutation of immunoglobulin variable region genes: focus on follicular lymphoma and multiple myeloma. Immunol Rev. 1998; 162: 281-292.","DOI":"10.1111\/j.1600-065X.1998.tb01448.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Solal-C\u00e9ligny P, Roy P, Colombat P et al.<\/i> Follicular lymphoma international prognostic index. Blood. 2004; 104: 1258-1265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Nooka AK, Nabhan C, Zhou X et al.<\/i> Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013; 24: 441-448.","DOI":"10.1093\/annonc\/mds429"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Bachy E, Maurer MJ, Habermann TM et al.<\/i> A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018; 132: 49-58.","DOI":"10.1182\/blood-2017-11-816405"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Alig S, Jurinovic V, Pastore A et al.<\/i> Impact of age on clinical risk scores in follicular lymphoma. Blood Adv. 2019; 3: 1033-1038.","DOI":"10.1182\/bloodadvances.2019032136"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Bosga-Bouwer AG, van Imhoff GW, Boonstra R et al.<\/i> Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 2003; 101: 1149-1154.","DOI":"10.1182\/blood.V101.3.1149"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Harris NL, Jaffe ES, Diebold J et al.<\/i> World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835-3849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Horn H, Schmelter C, Leich E et al.<\/i> Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011; 96: 1327-1334.","DOI":"10.3324\/haematol.2011.042531"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Shustik J, Quinn M, Connors JM et al.<\/i> Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2011; 22: 1164-1169.","DOI":"10.1093\/annonc\/mdq574"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Wahlin BE, Yri OE, Kimby E et al.<\/i> Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012; 156: 225-233.","DOI":"10.1111\/j.1365-2141.2011.08942.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 \u00c1lvaro T, Lejeune M, Salvad\u00f3 MT et al.<\/i> Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006; 24: 5350-5357.","DOI":"10.1200\/JCO.2006.06.4766"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Canioni D, Salles G, Mounier N et al.<\/i> High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008; 26: 440-446.","DOI":"10.1200\/JCO.2007.12.8298"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Carreras J, Lopez-Guillermo A, Fox BC et al.<\/i> High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006; 108: 2957-2964.","DOI":"10.1182\/blood-2006-04-018218"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Carreras J, Lopez-Guillermo A, Kikuti YY et al.<\/i> High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. J Clin Exp Hematop. 2019; 59: 1-16.","DOI":"10.3960\/jslrt.19003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Carreras J, Lopez-Guillermo A, Roncador G et al.<\/i> High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009; 27: 1470-1476.","DOI":"10.1200\/JCO.2008.18.0513"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Carreras J, Kikuti YY, Miyaoka M et al.<\/i> Artificial Intelligence Analysis of the Gene Expression of Follicular Lymphoma Predicted the Overall Survival and Correlated with the Immune Microenvironment Response Signatures. Mach Learn Knowl Extr. 2020; 2: 647-671.","DOI":"10.3390\/make2040035"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Carreras J, Kikuti YY, Miyaoka M et al.<\/i> The Use of the Random Number Generator and Artificial Intelligence Analysis for Dimensionality Reduction of Follicular Lymphoma Transcriptomic Data. BioMedInformatics. 2022; 2: 268-280.","DOI":"10.3390\/biomedinformatics2020017"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Dave SS, Wright G, Tan B et al.<\/i> Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351: 2159-2169.","DOI":"10.1056\/NEJMoa041869"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Farinha P, Kyle AH, Minchinton AI et al.<\/i> Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica. 2010; 95: 2157-2160.","DOI":"10.3324\/haematol.2009.021766"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Farinha P, Masoudi H, Skinnider BF et al.<\/i> Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005; 106: 2169-2174.","DOI":"10.1182\/blood-2005-04-1565"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Glas AM, Knoops L, Delahaye L et al.<\/i> Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007; 25: 390-398.","DOI":"10.1200\/JCO.2006.06.1648"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Klapper W, Hoster E, R\u00f6lver L et al.<\/i> Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007; 25: 3330-3336.","DOI":"10.1200\/JCO.2006.10.5833"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Kumar E, Pickard L, Okosun J. Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation. Br J Haematol. 2021; 194: 810-821.","DOI":"10.1111\/bjh.17383"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 K\u00fcppers R. Prognosis in follicular lymphoma--it\u2019s in the microenvironment. N Engl J Med. 2004; 351: 2152-2153.","DOI":"10.1056\/NEJMp048257"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Lee AM, Clear AJ, Calaminici M et al.<\/i> Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006; 24: 5052-5059.","DOI":"10.1200\/JCO.2006.06.4642"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Tamma R, Ingravallo G, Annese T et al.<\/i> Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. J Clin Med. 2022; 11: 1257.","DOI":"10.3390\/jcm11051257"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Taskinen M, Jantunen E, Kosma VM et al.<\/i> Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. Eur J Cancer. 2010; 46: 2506-2512.","DOI":"10.1016\/j.ejca.2010.06.014"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Lepp\u00e4 S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007; 13: 5784-5789.","DOI":"10.1158\/1078-0432.CCR-07-0778"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Tobin JWD, Keane C, Gunawardana J et al.<\/i> Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. J Clin Oncol. 2019; 37: 3300-3309.","DOI":"10.1200\/JCO.18.02365"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Valero JG, Matas-C\u00e9spedes A, Arenas F et al.<\/i> The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021; 35: 2635-2649.","DOI":"10.1038\/s41375-021-01201-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007; 13: 388-397.","DOI":"10.1158\/1078-0432.CCR-06-1734"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Louissaint A Jr, Schafernak KT, Geyer JT et al.<\/i> Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016; 128: 1093-1100.","DOI":"10.1182\/blood-2015-12-682591"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Schmidt J, Ramis-Zaldivar JE, Nadeu F et al.<\/i> Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood. 2017; 130: 323-327.","DOI":"10.1182\/blood-2017-03-776278"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Schmidt J, Gong S, Marafioti T et al.<\/i> Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood. 2016; 128: 1101-1111.","DOI":"10.1182\/blood-2016-03-703819"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Nann D, Ramis-Zaldivar JE, M\u00fcller I et al.<\/i> Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv. 2020; 4: 5652-5665.","DOI":"10.1182\/bloodadvances.2020002944"},{"key":"54","unstructured":"54 JC. BJFAA. Pathobiology of follicular lymphoma. UpToDate. 2023."},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Loeffler-Wirth H, Kreuz M, Schmidt M et al.<\/i> Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape. Cancers (Basel). 2022; 14: 3434.","DOI":"10.3390\/cancers14143434"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Jaffe ES, Carbone A. Evolution in the Definition of Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: A Model for the Future of Personalized Medicine. Hemato. 2022; 3: 466-474.","DOI":"10.3390\/hemato3030032"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Menon MP, Hutchinson L, Garver J, Jaffe ES, Woda BA. Transformation of follicular lymphoma to Epstein-Barr virus-related Hodgkin-like lymphoma. J Clin Oncol. 2013; 31: e53-e56.","DOI":"10.1200\/JCO.2012.43.2377"},{"key":"58","unstructured":"58 Bloomfield CD, Arthur DC, Frizzera G et al.<\/i> Nonrandom chromosome abnormalities in lymphoma. Cancer Res. 1983; 43: 2975-2984."},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Rowley JD. Chromosome studies in the non-Hodgkin\u2019s lymphomas: the role of the 14;18 translocation. J Clin Oncol. 1988; 6: 919-925.","DOI":"10.1200\/JCO.1988.6.5.919"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Raghavan SC, Swanson PC, Wu X, Hsieh CL, Lieber MR. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature. 2004; 428: 88-93.","DOI":"10.1038\/nature02355"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Eguchi Y, Ewert DL, Tsujimoto Y. Isolation and characterization of the chicken bcl-2 gene: expression in a variety of tissues including lymphoid and neuronal organs in adult and embryo. Nucleic Acids Res. 1992; 20: 4187-4192.","DOI":"10.1093\/nar\/20.16.4187"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Levy D, Bertoldi ERM, Ruiz JLM, Pereira J, Bydlowski SP. Presence of t(14;18) translocation in healthy individuals varies according to ethnic background in the Brazilian population. Braz J Med Biol Res. 2017; 50: e6172.","DOI":"10.1590\/1414-431x20176172"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Roulland S, Lebailly P, Lecluse Y et al.<\/i> Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia. 2006; 20: 158-162.","DOI":"10.1038\/sj.leu.2404035"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Sch\u00fcler F, Hirt C, D\u00f6lken G. Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biol. 2003; 13: 203-209.","DOI":"10.1016\/S1044-579X(03)00016-6"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Porter AG, J\u00e4nicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6: 99-104.","DOI":"10.1038\/sj.cdd.4400476"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2\/Bax switch. Cancer Cell. 2005; 8: 5-6.","DOI":"10.1016\/j.ccr.2005.06.012"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Boise LH, Gonz\u00e1lez-Garc\u00eda M, Postema CE et al.<\/i> bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74: 597-608.","DOI":"10.1016\/0092-8674(93)90508-N"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Oltval ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell. 1993; 74: 609-619.","DOI":"10.1016\/0092-8674(93)90509-O"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Ghia P, Boussiotis VA, Schultze JL et al.<\/i> Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998; 91: 244-251.","DOI":"10.1182\/blood.V91.1.244.244_244_251"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Schraders M, de Jong D, Kluin P, Groenen P, van Krieken H. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in theBCL2 gene or by absence of the t(14;18) translocation. J Pathol. 2005; 205: 329-335.","DOI":"10.1002\/path.1689"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Katzenberger T, Kalla J, Leich E et al.<\/i> A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009; 113: 1053-1061.","DOI":"10.1182\/blood-2008-07-168682"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Siddiqi IN, Friedman J, Barry-Holson KQ et al.<\/i> Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36\/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016; 29: 570-581.","DOI":"10.1038\/modpathol.2016.51"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 D\u00edaz-Alderete A, Doval A, Camacho F et al.<\/i> Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features. Leuk Lymphoma. 2008; 49: 95-101.","DOI":"10.1080\/10428190701742472"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Miyaoka M, Kikuti YY, Carreras J et al.<\/i> Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements. Mod Pathol. 2018; 31: 313-326.","DOI":"10.1038\/modpathol.2017.134"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Ikoma H, Miyaoka M, Hiraiwa S et al.<\/i> Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements. Pathol Int. 2022; 72: 321-331.","DOI":"10.1111\/pin.13223"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Takeoka K, Maekawa F, Nakagawa M et al.<\/i> MYC\/BCL2 double- and MYC\/BCL2\/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21). J Clin Exp Hematop. 2022; 62: 258-267.","DOI":"10.3960\/jslrt.22030"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Ci W, Polo JM, Cerchietti L et al.<\/i> The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009; 113: 5536-5548.","DOI":"10.1182\/blood-2008-12-193037"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Leung W, Teater M, Durmaz C et al.<\/i> SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discov. 2022; 12: 1782-1803.","DOI":"10.1158\/2159-8290.CD-21-1514"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007; 76: 1-22.","DOI":"10.1146\/annurev.biochem.76.061705.090740"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Teater M, Dominguez PM, Redmond D et al.<\/i> AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat Commun. 2018; 9: 222.","DOI":"10.1038\/s41467-017-02595-w"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Fairfax KA, Gantier MP, Mackay F, Williams BRG, McCoy CE. IL-10 regulates Aicda expression through miR-155. J Leukoc Biol. 2015; 97: 71-78.","DOI":"10.1189\/jlb.2A0314-178R"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Zan H, Casali P. Regulation of Aicda expression and AID activity. Autoimmunity. 2013; 46: 83-101.","DOI":"10.3109\/08916934.2012.749244"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Miyaoka M, Kikuti YY, Carreras J et al.<\/i> AID is a poor prognostic marker of high\u2010grade B\u2010cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements. Pathol Int. 2022; 72: 35-42.","DOI":"10.1111\/pin.13182"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997; 276: 589-592.","DOI":"10.1126\/science.276.5312.589"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Ye BH, Cattoretti G, Shen Q et al.<\/i> The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997; 16: 161-170.","DOI":"10.1038\/ng0697-161"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol. 2010; 105: 193-210.","DOI":"10.1016\/S0065-2776(10)05007-8"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Cheung KJ, Johnson NA, Affleck JG et al.<\/i> Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010; 70: 9166-9174.","DOI":"10.1158\/0008-5472.CAN-10-2460"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Cheung KJ, Shah SP, Steidl C et al.<\/i> Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009; 113: 137-148.","DOI":"10.1182\/blood-2008-02-140616"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Launay E, Pangault C, Bertrand P et al.<\/i> High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012; 26: 559-562.","DOI":"10.1038\/leu.2011.266"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Gaidano G, Ballerini P, Gong JZ et al.<\/i> p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 1991; 88: 5413-5417.","DOI":"10.1073\/pnas.88.12.5413"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Schwaenen C, Viardot A, Berger H et al.<\/i> Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer. 2009; 48: 39-54.","DOI":"10.1002\/gcc.20617"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Kridel R, Mottok A, Farinha P et al.<\/i> Cell of origin of transformed follicular lymphoma. Blood. 2015; 126: 2118-2127.","DOI":"10.1182\/blood-2015-06-649905"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Pasqualucci L, Khiabanian H, Fangazio M et al.<\/i> Genetics of follicular lymphoma transformation. Cell Rep. 2014; 6: 130-140.","DOI":"10.1016\/j.celrep.2013.12.027"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Green MR, Gentles AJ, Nair RV et al.<\/i> Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013; 121: 1604-1611.","DOI":"10.1182\/blood-2012-09-457283"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Pasqualucci L, Dominguez-Sola D, Chiarenza A et al.<\/i> Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471: 189-195.","DOI":"10.1038\/nature09730"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Morin RD, Mendez-Lago M, Mungall AJ et al.<\/i> Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476: 298-303.","DOI":"10.1038\/nature10351"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 B\u00f6d\u00f6r C, Grossmann V, Popov N et al.<\/i> EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013; 122: 3165-3168.","DOI":"10.1182\/blood-2013-04-496893"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Okosun J, B\u00f6d\u00f6r C, Wang J et al.<\/i> Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46: 176-181.","DOI":"10.1038\/ng.2856"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Green MR, Kihira S, Liu CL et al.<\/i> Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA. 2015; 112: E1116-E1125.","DOI":"10.1073\/pnas.1501199112"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Kridel R, Chan FC, Mottok A et al.<\/i> Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med. 2016; 13: e1002197.","DOI":"10.1371\/journal.pmed.1002197"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018; 131: 595-604.","DOI":"10.1182\/blood-2017-08-737361"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Schmidt J, Ramis-Zaldivar JE, Bonzheim I et al.<\/i> CREBBP gene mutations are frequently detected in in situ follicular neoplasia. Blood. 2018; 132: 2687-2690.","DOI":"10.1182\/blood-2018-03-837039"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103 Okosun J, Wolfson RL, Wang J et al.<\/i> Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016; 48: 183-188.","DOI":"10.1038\/ng.3473"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Ortega-Molina A, Deleyto-Seldas N, Carreras J et al.<\/i> Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nat Metab. 2019; 1: 775-789.","DOI":"10.1038\/s42255-019-0098-8"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Krysiak K, Gomez F, White BS et al.<\/i> Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017; 129: 473-483.","DOI":"10.1182\/blood-2016-07-729954"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Davies AJ, Lee AM, Taylor C et al.<\/i> A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia. 2005; 19: 1459-1465.","DOI":"10.1038\/sj.leu.2403802"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Lo Coco F, Gaidano G, Louie DC et al.<\/i> p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993; 82: 2289-2295.","DOI":"10.1182\/blood.V82.8.2289.bloodjournal8282289"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Sander CA, Yano T, Clark HM et al.<\/i> p53 mutation is associated with progression in follicular lymphomas. Blood. 1993; 82: 1994-2004.","DOI":"10.1182\/blood.V82.7.1994.bloodjournal8271994"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Pastore A, Jurinovic V, Kridel R et al.<\/i> Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16: 1111-1122.","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110 Los-de Vries GT, Stevens WBC, van Dijk E et al.<\/i> Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III\/IV. Blood Adv. 2022; 6: 5482-5493.","DOI":"10.1182\/bloodadvances.2022008355"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Morschhauser F, Tilly H, Chaidos A et al.<\/i> Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020; 21: 1433-1442.","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112 Doba\u00f1o-L\u00f3pez C, Araujo-Ayala F, Serrat N, Valero JG, P\u00e9rez-Gal\u00e1n P. Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. Cancers (Basel). 2021; 13: 641.","DOI":"10.3390\/cancers13040641"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 L\u00f3pez C, Mozas P, L\u00f3pez-Guillermo A, Be\u00e0 S. Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice. Hemato. 2022; 3: 595-614.","DOI":"10.3390\/hemato3040041"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114 Blaker YN, Spetalen S, Brodtkorb M et al.<\/i> The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol. 2016; 175: 102-114.","DOI":"10.1111\/bjh.14201"},{"key":"115","unstructured":"115 U.S. Food & Drug Administration (FDA) 2023 [Available from: https:\/\/www.fda.gov\/."},{"key":"116","unstructured":"116 . 2023 [Available from: https:\/\/www.drugs.com\/."},{"key":"117","doi-asserted-by":"crossref","unstructured":"117 Sorigue M, Ca\u00f1amero E, Sancho JM. Precision medicine in follicular lymphoma: focus on predictive biomarkers. Hematol Oncol. 2020; 38: 625-639.","DOI":"10.1002\/hon.2781"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118 Turing AM. I.\u2014COMPUTING MACHINERY AND INTELLIGENCE. Mind. 1950; LIX: 433-460.","DOI":"10.1093\/mind\/LIX.236.433"},{"key":"119","unstructured":"119 McCarthy J. WHAT IS ARTIFICIAL INTELLIGENCE? Computer Science Department, Stanford University. 2007."},{"key":"120","unstructured":"120 Russell S, Norvig P. Artificial Intelligence: A Modern Approach, 4th US ed. Aug 22, 2022 ed2022 Aug 22, 2022."},{"key":"121","unstructured":"121 Open AI. Introducing ChatGPT 2023 [Available from: https:\/\/openai.com\/blog\/chatgpt."},{"key":"122","doi-asserted-by":"crossref","unstructured":"122 Yoshida H, Kiyuna T. Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology. World J Gastroenterol. 2021; 27: 2818-2833.","DOI":"10.3748\/wjg.v27.i21.2818"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123 Hamamoto R, Suvarna K, Yamada M et al.<\/i> Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine. Cancers (Basel). 2020; 12: 3532.","DOI":"10.3390\/cancers12123532"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124 Nojima S, Terayama K, Shimoura S et al.<\/i> A deep learning system to diagnose the malignant potential of urothelial carcinoma cells in cytology specimens. Cancer Cytopathol. 2021; 129: 984-995.","DOI":"10.1002\/cncy.22443"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125 Maruyama K, Mei S, Sakaguchi H et al.<\/i> Diagnosis of Choroidal Disease With Deep Learning-Based Image Enhancement and Volumetric Quantification of Optical Coherence Tomography. Transl Vis Sci Technol. 2022; 11: 22.","DOI":"10.1167\/tvst.11.1.22"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126 Horie Y, Yoshio T, Aoyama K et al.<\/i> Diagnostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks. Gastrointest Endosc. 2019; 89: 25-32.","DOI":"10.1016\/j.gie.2018.07.037"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127 Kobayashi K, Bolatkan A, Shiina S, Hamamoto R. Fully-Connected Neural Networks with Reduced Parameterization for Predicting Histological Types of Lung Cancer from Somatic Mutations. Biomolecules. 2020; 10: 1249.","DOI":"10.3390\/biom10091249"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128 Hirokawa M, Niioka H, Suzuki A et al.<\/i> Application of deep learning as an ancillary diagnostic tool for thyroid FNA cytology. Cancer Cytopathol. 2023; 131: 217-225.","DOI":"10.1002\/cncy.22669"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Yamamoto Y, Carreras J, Shimizu T et al.<\/i> Anti-HBV drug entecavir ameliorates DSS-induced colitis through PD-L1 induction. Pharmacol Res. 2022; 179: 105918.","DOI":"10.1016\/j.phrs.2021.105918"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130 Takenaka K, Kawamoto A, Okamoto R, Watanabe M, Ohtsuka K. Artificial intelligence for endoscopy in inflammatory bowel disease. Intest Res. 2022; 20: 165-170.","DOI":"10.5217\/ir.2021.00079"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131 Stidham RW, Takenaka K. Artificial Intelligence for Disease Assessment in Inflammatory Bowel Disease: How Will it Change Our Practice? Gastroenterology. 2022; 162: 1493-1506.","DOI":"10.1053\/j.gastro.2021.12.238"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132 Ohara J, Nemoto T, Maeda Y et al.<\/i> Deep learning-based automated quantification of goblet cell mucus using histological images as a predictor of clinical relapse of ulcerative colitis with endoscopic remission. J Gastroenterol. 2022; 57: 962-970.","DOI":"10.1007\/s00535-022-01924-1"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Noguchi T, Ando T, Emoto S et al.<\/i> Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis-Associated Cancer or Dysplasia. Inflamm Bowel Dis. 2022; 28: 1072-1080.","DOI":"10.1093\/ibd\/izab350"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134 Carreras J. Artificial Intelligence Analysis of Celiac Disease Using an Autoimmune Discovery Transcriptomic Panel Highlighted Pathogenic Genes including BTLA. Healthcare (Basel). 2022; 10: 1550.","DOI":"10.3390\/healthcare10081550"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135 Carreras J. Artificial Intelligence Analysis of Ulcerative Colitis Using an Autoimmune Discovery Transcriptomic Panel. Healthcare (Basel). 2022; 10: 1476.","DOI":"10.3390\/healthcare10081476"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136 Maeda Y, Watanabe T, Izumi T et al.<\/i> Biomolecular Fluorescence Complementation Profiling and Artificial Intelligence Structure Prediction of the Kaposi\u2019s Sarcoma-Associated Herpesvirus ORF18 and ORF30 Interaction. Int J Mol Sci. 2022; 23: 9647.","DOI":"10.3390\/ijms23179647"},{"key":"137","unstructured":"137 Tomita H, Yamashiro T, Iida G et al.<\/i> Unenhanced CT texture analysis with machine learning for differentiating between nasopharyngeal cancer and nasopharyngeal malignant lymphoma. Nagoya J Med Sci. 2021; 83: 135-149."},{"key":"138","doi-asserted-by":"crossref","unstructured":"138 Hashimoto N, Takagi Y, Masuda H et al.<\/i> Case-based similar image retrieval for weakly annotated large histopathological images of malignant lymphoma using deep metric learning. Med Image Anal. 2023; 85: 102752.","DOI":"10.1016\/j.media.2023.102752"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139 Carreras J, Nakamura N, Hamoudi R. Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series. Healthcare (Basel). 2022; 10: 155.","DOI":"10.3390\/healthcare10010155"},{"key":"140","unstructured":"140 Carreras J, Hamoudi R, Nakamura N. Artificial Intelligence Analysis of Gene Expression Data Predicted the Prognosis of Patients with Diffuse Large B-Cell Lymphoma. Tokai J Exp Clin Med. 2020; 45: 37-48."},{"key":"141","doi-asserted-by":"crossref","unstructured":"141 Miyoshi H, Sato K, Kabeya Y et al.<\/i> Deep learning shows the capability of high-level computer-aided diagnosis in malignant lymphoma. Lab Invest. 2020; 100: 1300-1310.","DOI":"10.1038\/s41374-020-0442-3"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142 Carreras J, Roncador G, Hamoudi R. Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels. Cancers (Basel). 2022; 14: 5318.","DOI":"10.3390\/cancers14215318"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143 K\u00fcppers R, Stevenson FK. Critical influences on the pathogenesis of follicular lymphoma. Blood. 2018; 131: 2297-2306.","DOI":"10.1182\/blood-2017-11-764365"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/3\/63_23014\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T05:07:20Z","timestamp":1696050440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/3\/63_23014\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23014","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23014"}}